NurExone Biologic Inc. faces a significant setback as its stock drops sharply in today's trading session.
Today, NurExone Biologic Inc. (NRX.V) is seeing a notable decline, with shares down by 10.45%. This downturn raises questions about the company's current standing and future prospects in the biotech sector.
Advertisement
NurExone Biologic Inc.
NRX.V
NRX.V
NurExone Biologic Inc.
WealthAwesomeMarket cap
$61.67M
52W high
$1.09
52W low
$0.43
1W change
+11.67%
Beta
0.45
Analyst Price Targets
Based on analyst covering NRX · as of Sep 17, 2026
Wall Street analysts forecast NRX stock price to rise 271.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.49
+271.8% Upside
Current Price
C$0.67
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on NRX's historical volatility
30-Day Vol
130.0%
Annualized
90-Day Vol
85.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.80
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.71 | C$0.45 – C$1.11 |
| 60 trading days | C$0.75 | C$0.40 – C$1.42 |
| 90 trading days | C$0.80 | C$0.37 – C$1.74 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should closely monitor NurExone's developments, especially in light of the recent financial results and corporate updates that may influence market sentiment.
NurExone's stock down 10.45% today
With a market cap of approximately CA$61.67 million, today's decline could significantly impact investor sentiment.
Bull case
Despite today's drop, NurExone has shown potential in the past through its collaborations and innovations in the biotech field, which could lead to a recovery.
Bear case
The lack of recent positive news and today's significant drop may suggest underlying issues that could affect investor confidence moving forward.
Stock Performance Overview
Advertisement
NurExone Biologic Inc. shares are down 10.45% today, closing at CA$0.60. This decline reflects a challenging market environment for the company, especially given the absence of recent positive developments or news that could boost investor confidence.
Market Sentiment and Future Outlook
The current market sentiment surrounding NurExone is cautious. Investors are likely reevaluating their positions following the latest financial results and corporate updates. With a market cap of CA$61.67 million, the impact of today's drop could resonate in future trading sessions. For more insights, check out the latest updates on NurExone's financial results.
What Lies Ahead for NurExone
Looking ahead, NurExone's ability to recover from today's decline will depend on its strategic decisions and potential collaborations. Investors should keep an eye on upcoming announcements that may influence the stock's trajectory. For further details on the company's performance, visit NurExone's stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
